These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39258622)

  • 21. Influence of previous COVID-19 exposure and vaccine type (CoronaVac, ChAdOx1 nCov-19 or BNT162b2) on antibody and cytokine (Th1 or Th2) responses.
    Padilla-Bórquez DL; Matuz-Flores MG; Hernández-Bello J; Rosas-Rodríguez JA; Turrubiates-Hernández FJ; García-Arellano S; González-Estevez G; Ceja-Galvez HR; Oregon-Romero E; López-Reyes A; Muñoz-Valle JF
    Hum Vaccin Immunother; 2024 Dec; 20(1):2394265. PubMed ID: 39246041
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Humoral immunity to SARS-CoV-2 in kidney transplant recipients and dialysis patients: IgA and IgG patterns unraveled after SARS-CoV-2 infection and vaccination.
    De Bouver C; Bouziotis J; Wijtvliet VPWM; Ariën KK; Mariën J; Heyndrickx L; Couttenye MM; de Fijter HJW; Mestrez F; Treille S; Mat O; Collart F; Allard SD; Vingerhoets L; Moons P; Abramowicz D; De Winter BY; Pipeleers L; Wissing KM; Ledeganck KJ
    Virol J; 2024 Jun; 21(1):138. PubMed ID: 38872127
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Heterologous and homologous COVID-19 mRNA vaccination schemes for induction of basic immunity show similar immunogenicity regarding long-term spike-specific cellular immunity in healthcare workers.
    Wagenhäuser I; Almanzar G; Förg FB; Stein A; Eiter I; Reusch J; Mees J; Herzog A; Vogel U; Frey A; Lâm TT; Schubert-Unkmeir A; Dölken L; Kurzai O; Frantz S; Gabel A; Petri N; Prelog M; Krone M
    Vaccine; 2024 Aug; 42(21):126132. PubMed ID: 39034219
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 25. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
    Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
    J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
    [No Abstract]   [Full Text] [Related]  

  • 26. Immune responses during COVID-19 breakthrough cases in vaccinated children and adolescents.
    Rivera-Pérez D; Méndez C; Diethelm-Varela B; Melo-González F; Vázquez Y; Meng X; Xin Q; Fasce RA; Fernández J; Mora J; Ramirez E; Acevedo ML; Valiente-Echeverría F; Soto-Rifo R; Grifoni A; Weiskopf D; Sette A; Astudillo P; Le Corre N; Abarca K; Perret C; González PA; Soto JA; Bueno SM; Kalergis AM
    Front Immunol; 2024; 15():1372193. PubMed ID: 38812507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
    Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
    Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers.
    Bayram A; Demirbakan H; Günel Karadeniz P; Erdoğan M; Koçer I
    J Med Virol; 2021 Sep; 93(9):5560-5567. PubMed ID: 34019704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program.
    van Leeuwen LPM; Grobben M; GeurtsvanKessel CH; Ellerbroek PM; de Bree GJ; Potjewijd J; Rutgers A; Jolink H; van de Veerdonk FL; van Gils MJ; de Vries RD; Dalm VASH;
    Front Immunol; 2024; 15():1390022. PubMed ID: 38698851
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety and immunogenicity of inactivated COVID-19 vaccine in health care workers.
    Benjamanukul S; Traiyan S; Yorsaeng R; Vichaiwattana P; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    J Med Virol; 2022 Apr; 94(4):1442-1449. PubMed ID: 34783049
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cellular and humoral immune responses to COVID-19 booster vaccination in Japanese dialysis patients.
    Yoshifuji A; Toda M; Oyama E; Nakayama T; Mise-Omata S; Kikuchi K; Yoshizawa M; Kato N; Wakai H; Koibuchi K; Morimoto K; Uwamino Y; Namkoong H; Shibata A; Wakabayashi K; Fujino M; Komatsu M; Mochizuki N; Kondo N; Yoshimura A; Hasegawa N; Ryuzaki M
    Clin Exp Nephrol; 2024 Jul; 28(7):674-682. PubMed ID: 38457030
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial.
    Han B; Song Y; Li C; Yang W; Ma Q; Jiang Z; Li M; Lian X; Jiao W; Wang L; Shu Q; Wu Z; Zhao Y; Li Q; Gao Q
    Lancet Infect Dis; 2021 Dec; 21(12):1645-1653. PubMed ID: 34197764
    [TBL] [Abstract][Full Text] [Related]  

  • 34. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
    Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
    Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Kinetics and persistence of cellular and humoral immune responses to SARS-CoV-2 vaccine in healthcare workers with or without prior COVID-19.
    Chivu-Economescu M; Bleotu C; Grancea C; Chiriac D; Botezatu A; Iancu IV; Pitica I; Necula LG; Neagu A; Matei L; Dragu D; Sultana C; Radu EL; Nastasie A; Voicu O; Ataman M; Nedeianu S; Mambet C; Diaconu CC; Ruta SM
    J Cell Mol Med; 2022 Feb; 26(4):1293-1305. PubMed ID: 35043552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
    Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
    Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The mRNA-1273 Vaccine Induces Cross-Variant Antibody Responses to SARS-CoV-2 With Distinct Profiles in Individuals With or Without Pre-Existing Immunity.
    Tejedor Vaquero S; de Campos-Mata L; Ramada JM; Díaz P; Navarro-Barriuso J; Ribas-Llaurado C; Rodrigo Melero N; Carolis C; Cerutti A; Gimeno R; Magri G
    Front Immunol; 2021; 12():737083. PubMed ID: 34539673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A prospective humoral immune monitoring study of kidney transplant recipients receiving three doses of SARS-CoV-2 mRNA vaccine.
    Borgogna C; Ferrante D; Rosso G; Guglielmetti G; Lo Cigno I; Raviola S; Caneparo V; Quaglia M; Cantaluppi V; Gariglio M
    J Med Virol; 2024 Jun; 96(6):e29710. PubMed ID: 38804187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
    Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
    Front Immunol; 2022; 13():918896. PubMed ID: 35757764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.